Page 100 - CPG มะเร็งปากมดลูก

94 แนวทางการป?องกันและรกั ษามะเรง็ ปากมดลูก

36 Rushforth GF. Osteosarcoma of the pelvis following radiotherapy for carcinoma of the cervix. Br J Radiol. 1974;47(554):149-52
37. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE,et al. Carboplatin dosage: prospective evaluation

of a simple formula based on renal function. J Clin Oncol.1989 ;7(11):1748-56.
38. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Common Terminology Criteria for Adverse Events (CTCAE)

Version 5.0 [Internet]. 2017.
39. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or

recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27:1069-74.
40. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite

Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10.
42. Thachanun Porntharukchareon, Panudda Srichomkwa. Endocrine Dysfunction Induced by Immune Checkpoint

Inhibitors . J Chulabhorn Royal Acad. 2019; 1(2): 35-52.
43. Brahmer JR, Lacchetti C, Schneider BJ. Management of Immune-Related Adverse Events in Patients Treated With

Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol
Off J Am Soc Clin Oncol. 2018;36(17):1714–68.
44. Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, et al. The current understanding of the endocrine effects
from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr 2018;2(3):ky021.
45. Stability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38:1-10.